| Literature DB >> 35906529 |
Chongtu Yang1,2, Yang Chen1,2, Chaoyang Wang1,2, Jiacheng Liu1,2, Songjiang Huang1,2, Chen Zhou1,2, Yingliang Wang1,2, Shuguang Ju1,2, Tongqiang Li1,2, Yaowei Bai1,2, Wei Yao1,2, Bin Xiong3,4.
Abstract
BACKGROUND: Targeted puncture of an appropriate portal venous branch during transjugular intrahepatic portosystemic shunt (TIPS) procedure may reduce the risk of postprocedural overt hepatic encephalopathy (HE). This study aimed to describe blood distribution under portography and combined it with puncture site to determine portal flow diversion, and to evaluate its prognostic value in predicting post-TIPS overt HE.Entities:
Keywords: Cirrhosis; Hepatic encephalopathy; Portal hypertension; Portography; Portosystemic shunt; Transjugular intrahepatic
Mesh:
Year: 2022 PMID: 35906529 PMCID: PMC9336111 DOI: 10.1186/s12876-022-02447-y
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 2.847
Fig. 1Blood distribution and portal flow diversion under portography. A, B, C Blood distribution. A Represents type A (unilateral type with the right portal branch receives blood from SV), B represents type B (unilateral type with the right branch receives blood from SMV), C represents type C (bilateral opacification). D, E, F Portal flow diversion. D Represents SV superiority type (TIPS shunt diverts blood from SV), E represents SMV superiority type (TIPS shunt diverts blood from SMV), F represents mixed type (type C regardless of the puncture site). G, H, I Flow diversion under portography during TIPS procedure. G Represents SV superiority type (case with type A and puncture of the right branch), H represents SMV superiority type (case with type A and puncture of the left branch), I represents mixed type (case with mixed type and puncture of the left branch). SV splenic vein, SMV superior mesenteric vein, PV portal vein
Fig. 2Flowchart of the patient selection protocol. TIPS transjugular intrahepatic portosystemic shunt, HCC hepatocellular carcinoma, CTPV cavernous transformation of portal vein, SV splenic vein, SMV superior mesenteric vein
Baseline characteristics of the study population
| Total | SV group | SMV group | Mixed group | ||
|---|---|---|---|---|---|
| Age* | 54.6 (12.0) | 54.2 (11.0) | 62.5 (11.6) | 53.6 (11.9) | 0.002 |
| Sex (Male) | 155 (63.8) | 26 (65.0) | 20 (80.0) | 109 (61.2) | 0.185 |
| Etiology | 0.277 | ||||
| Virus related | 168 (69.1) | 28 (70.0) | 14 (56.0) | 126 (70.8) | |
| Alcohol related | 22 (9.05) | 5 (12.5) | 2 (8.00) | 15 (8.43) | |
| AIH | 25 (10.3) | 3 (7.50) | 2 (8.00) | 20 (11.2) | |
| Others | 28 (11.5) | 4 (10.0) | 7 (28.0) | 17 (9.55) | |
| TIPS indication | < 0.001 | ||||
| Variceal bleeding | 212 (87.2) | 31 (77.5) | 17 (68.0) | 164 (92.1) | |
| Refractory ascites | 31 (12.8) | 9 (22.5) | 8 (32.0) | 14 (7.87) | |
| Child–Pugh score* | 7.53 (1.61) | 7.15 (1.53) | 7.96 (1.10) | 7.55 (1.67) | 0.131 |
| Child–Pugh class | 0.065 | ||||
| A | 62 (26.2) | 13 (32.5) | 3 (12.0) | 46 (26.7) | |
| B | 153 (64.6) | 25 (62.5) | 22 (88.0) | 106 (61.6) | |
| C | 22 (9.28) | 2 (5.00) | 0 (0.00) | 20 (11.6) | |
| MELD score* | 11.9 (3.68) | 11.4 (3.10) | 13.0 (3.45) | 11.9 (3.82) | 0.238 |
| MELD-Na score* | 12.8 (4.71) | 12.3 (4.40) | 14.2 (4.77) | 12.7 (4.76) | 0.263 |
| Ascites | 0.005 | ||||
| Mild | 84 (34.9) | 10 (25.6) | 3 (12.0) | 71 (40.1) | |
| Moderate | 39 (16.2) | 9 (23.1) | 5 (20.0) | 25 (14.1) | |
| Severe | 66 (27.4) | 6 (15.4) | 13 (52.0) | 47 (26.6) | |
| Spontaneous porto-systemic shunt (Yes) | 94 (38.7) | 13 (32.5) | 11 (44.0) | 70 (39.3) | 0.828 |
| PV diameter (mm)* | 15.4 (3.28) | 14.5 (2.69) | 15.3 (3.99) | 15.6 (3.28) | 0.172 |
| Bilirubin (µmol/L) | 27.9 (28.3) | 22.8 (11.4) | 27.0 (13.1) | 29.3 (32.3) | 0.419 |
| Albumin (g/L) | 31.3 (5.53) | 31.9 (5.37) | 29.3 (5.53) | 31.4 (5.54) | 0.144 |
| ALT (U/L) | 37.1 (80.0) | 32.8 (22.4) | 37.6 (30.5) | 38.0 (92.6) | 0.935 |
| Creatinine (µmol/L) | 76.9 (60.6) | 74.5 (27.3) | 92.6 (75.7) | 75.1 (63.7) | 0.391 |
| Sodium (mmol/L) | 139 (4.43) | 138 (3.94) | 140 (5.61) | 139 (4.36) | 0.576 |
| Prothrombin time (s) | 16.8 (2.49) | 16.5 (2.52) | 17.0 (1.69) | 16.8 (2.58) | 0.703 |
| INR | 1.39 (0.26) | 1.36 (0.26) | 1.41 (0.18) | 1.39 (0.27) | 0.679 |
| Stent diameter | 0.520 | ||||
| 6 mm | 108 (44.4) | 19 (47.5) | 12 (48.0) | 77 (43.3) | |
| 7 mm | 87 (35.8) | 16 (40.0) | 6 (24.0) | 65 (36.5) | |
| 8 mm | 48 (19.8) | 5 (12.5) | 7 (28.0) | 36 (20.2) | |
| Pre-TIPS PPG* | 36.8 (7.63) | 34.8 (5.81) | 33.7 (10.7) | 37.5 (7.51) | 0.080 |
| Post-TIPS PPG* | 15.9 (5.41) | 15.3 (4.20) | 13.1 (7.39) | 16.3 (5.33) | 0.088 |
| Portography | 0.169 | ||||
| Through SV | 221 (90.9) | 37 (92.5) | 21 (84.0) | 164 (92.1) | |
| Through SMV | 22 (9.1) | 3 (7.5) | 5 (16.0) | 14 (7.9) | |
| Puncture site | < 0.001 | ||||
| Left branch | 112 (46.1) | 7 (17.5) | 17 (68.0) | 88 (49.4) | |
| Right branch | 131 (53.9) | 33 (82.5) | 8 (32.0) | 90 (50.6) | |
| Embolization | 166 (68.3) | 29 (72.5) | 15 (60.0) | 122 (68.5) | 0.569 |
*Data were expressed as means and standard deviation; Other data were presented as frequencies and percentages
AIH autoimmune hepatitis, CTPV cavernous transformation of portal vein, MELD model for end-stage liver disease, PV portal vein, SV splenic vein, SMV superior mesenteric vein, ALT alanine aminotransferase, INR international normalized ratio, PPG portal pressure gradient
Summary of outcome measurements during follow-up
| Total | SV group | SMV group | Mixed group | |
|---|---|---|---|---|
| Follow-up period (m)* | 15.8 (9.4–26.5) | 13.5 (5.7–26.2) | 12.9 (4.7–21.4) | 16.9 (5.7–28.3) |
| Overt HE | 67 (27.6) | 5 (12.5) | 18 (72.0) | 44 (24.7) |
| Grade III or higher | 59 (24.2) | 3 (7.5) | 16 (64.0) | 40 (22.4) |
| Recurrent | 21 (8.6) | 2 (5.0) | 8 (32.0) | 11 (6.2) |
| Precipitant | ||||
| High-protein intake | 25 (37.3) | 2 (40.0) | 5 (27.8) | 18 (40.9) |
| Rebleeding | 9 (13.4) | 0 (0.0) | 2 (11.1) | 7 (15.9) |
| Liver failure | 18 (26.9) | 2 (40.0) | 7 (38.9) | 9 (20.5) |
| Unclear | 15 (22.4) | 1 (20.0) | 4 (22.2) | 10 (22.7) |
| With ammonia elevation | 81 (66.3) | 12 (54.5) | 17 (80.9) | 52 (65.8) |
| Elevation level* (μmol/L) | 9 (− 7–30) | 4 (− 10–9) | 31 (10–36) | 8 (− 7–26) |
| With ammonia elevation | 57 (76.0) | 9 (75.0) | 12 (92.3) | 36 (72.0) |
| Elevation level* (μmol/L) | 20 (4–52) | 18 (1–30) | 45 (23–60) | 18 (− 1–55) |
*Data were expressed as median (interquartile range); Other data were expressed as frequencies (percentages)
†For the secondary outcome 1, the results were available in 122 patients (22 patients for the SV group, 21 for the SMV group and 79 for the Mixed group)
§For the secondary outcome 2, the results were available in 75 patients (12 patients for the SV group, 13 for the SMV group and 50 for the Mixed group)
Fig. 3Post-TIPS overt hepatic encephalopathy in the study population. A Kaplan–Meier curves of patients stratified by flow diversion (SV group, SMV group and mixed group), B Kaplan–Meier curves of patients stratified by puncture site (left branch group and right branch group). SV splenic vein, SMV superior mesenteric vein, HR hazard ratio, CI confidence interval
Association between diversion type and incidence of outcomes
| Diversion type | HR/OR (95% CI) | ||
|---|---|---|---|
| Model A | Model B | Model C | |
| Mixed | Ref | Ref | Ref |
| SV superiority | 0.57 (0.22–1.45) | 0.58 (0.24–1.47) | 0.57 (0.22–1.48) |
| SMV superiority | 3.77 (2.09–6.78) | 3.72 (2.05–6.75) | 3.70 (2.01–6.80) |
| Mixed | Ref | Ref | Ref |
| SV superiority | 0.55 (0.20–1.51) | 0.58 (0.21–1.59) | 0.52 (0.18–1.48) |
| SMV superiority | 2.94 (0.91–11.75) | 2.98 (0.93–11.94) | 3.21 (1.07–13.14) |
| Mixed | Ref | Ref | Ref |
| SV superiority | 1.05 (0.28–5.88) | 1.10 (0.29–6.20) | 1.02 (0.26–5.89) |
| SMV superiority | 3.69 (0.57–73.81) | 3.76 (0.58–75.43) | 3.82 (0.59–76.94) |
Model A was adjusted for age and Child–Pugh score
Model B was adjusted for age, Child–Pugh score and post-TIPS portal pressure gradient
Model C was adjusted for age, Child–Pugh score, post-TIPS portal pressure gradient and puncture site (left/right PV branch)
*For the secondary outcomes, effect of diversion type on the outcomes were evaluated by logistic regression models with odds ratios
Ref reference, HR hazard ratio, OR odds ratio, CI confidence interval, HE hepatic encephalopathy
Fig. 4Change of ammonia level before and after TIPS creation. A and C Ammonia level before and at 3 days after procedure from 122 patients. B and D Ammonia level before and at 1 month after procedure from 75 patients. A, B In scatterplots, points below the diagonal line represent cases with the 3 days/1 month ammonia lever lower than the baseline level, and points above the diagonal line represent cases with the 3 days/1 month ammonia level higher than the baseline level. C, D Boxplots show the median (interquartile range) of ammonia level. P value were calculated using Mann–Whitney U tests